Media More Coverage

Einstein in the Media

The Wall Street Journal highlights groundbreaking research by Steven Walkley, D.V.M., Ph.D., that has led to treatment options for the rare condition Niemann-Pick Type C. In a lengthy cover story covering at least six years of reporting, journalist Amy Marcus details the passion that drove Walkley to continue his research on the drug cyclodextrin – and explores how parents and scientists have joined forces to find more effective treatments.

(Thursday, November 14, 2013)

 

The New York Daily News interviews Robert Marion, M.D., and Steven Walkley, D.V.M., Ph.D., about Einstein’s leap year event showcasing the talents of young people with rare diseases in order to raise awareness of their conditions. The event will highlight the abilities of the participants and encourage partnerships among researchers to help find much-needed treatments. Dr. Marion is chief of genetics and developmental medicine at Einstein and Montefiore Medical Center. Dr. Walkley is director of the Rose F. Kennedy Intellectual and Developmental Disabilities Research Center at Einstein. (Wednesday, February 29, 2012)

 

The Wall Street Journal highlights remarks by Steven Walkley, D.V.M., Ph.D., on the NIH's Therapeutics for Rare and Neglected Diseases (TRND) program, which just announced funding for five projects struggling to develop drug therapies for rare diseases, including the fatal neurodegenerative disease Niemann-Pick Type C (NPC). Dr. Walkley, who helped identify a potential drug treatment for NPC by testing FDA-approved medications, notes that the TRND program is promising, but offers no guarantees. Dr. Walkley is professor in the Dominick P. Purpura Department of Neuroscience. (Tuesday, July 27, 2010)

More coverage on other stories